Clinical Trial Search

Primary: Percent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 15 — -62.48; -8.77; -48.21; -4.93 percent change — p== 0.0009

Primary: Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR) — 11.3; 13.0; 12.2; 6.9 Percentage of Participants

Primary: Number of Participants With Clinical Benefit (CB) — 13 Participants

Primary: Number of Participants With Serious Adverse Events — 0; 0; 0 Participants

Primary: Number of Participants Who Achieved a Confirmed Response — 2; 6; 1; 2 Participants

Primary: Dysplasia in Barrett Esophagus (BE) — 4; 4; 3; 23 Participants — p=0.992

Primary: Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax) — 19.92; 18.83 centimeter (cm) — p=0.0062

Primary: Changes From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) — -1.0; -1.5; -4.0; -5.5 units on a scale — p=<0.0001

Primary: Summary of Analysis of Progression-Free Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed…

Primary: Response Rate — 17 Participants

Primary: Number of Subjects With Treatment-Emergent Adverse Events — 20; 10 Participants — p=0.963

Primary: Percent of Participants With at Least One Occurrence of Treatment-emergent Renal Serious Adverse Events (SAEs) (SAF) — 1.9; 14.3 percentage of participants

Primary: Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) — 0.98; 0.89; 0.69…

Primary: Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB) — 6582.0; 6738.3; 5252.2; 5471.9 ng*hr/mL

Primary: Percentage of Participants Experiencing at Least One Adverse Event (AEs) in the Core Period — 96.3; 100.0 percentage of participants